Daliresp, the brand name for the drug roflumilast, is a prescription medication used to reduce the risk of exacerbations, or flare-ups, in patients with severe chronic obstructive pulmonary disease (COPD). It is not a bronchodilator and is not meant for the relief of sudden breathing problems. Given that it's a specialty medication, the cost can be substantial without proper planning. The final price you pay depends on several factors, including whether you use the brand or generic, your insurance coverage, and access to savings programs.
Brand vs. Generic: The Most Significant Cost Factor
For many years, Daliresp was only available as a brand-name drug, which came with a high price tag. However, the introduction of the generic version, roflumilast, in 2022 revolutionized patient access and affordability. Generic medications are approved by the FDA as being the same high quality, strength, and potency as their brand-name counterparts, but they typically cost a fraction of the price.
- Brand-Name Daliresp: Without insurance or assistance, the cash price for a 30-day supply can range from approximately $450 to over $565 for the 500mcg strength.
- Generic Roflumilast: The cash price for the generic version is substantially lower. For example, some wholesale prices for a 30-tablet bottle of 500mcg roflumilast are listed around $40, though retail prices may differ.
This significant difference highlights why consulting your doctor about switching to the generic form is the first and most crucial step in managing the cost of this medication.
How Insurance Coverage Influences Price
Your insurance plan, including commercial plans, Medicare, or Medicaid, plays a major role in determining your final out-of-pocket expense. It is important to remember that prices vary widely depending on the specifics of your plan.
- Commercial Insurance: Many commercially insured patients may still face high out-of-pocket costs, such as copays or coinsurance, especially if their plan requires them to pay a percentage of the drug's cost.
- Medicare Part D: Coverage for Daliresp through Medicare can also be complex, with costs varying depending on the plan's specific copay range and which coverage phase you are in.
- Understanding Your Plan: Always contact your insurance provider directly to determine your specific copay and deductible responsibilities for either brand-name Daliresp or generic roflumilast.
Daliresp and Roflumilast Cost Comparison
Below is a comparison of potential costs under different scenarios. It is important to note these are estimates, and actual prices will depend on your specific pharmacy, location, and plan. It's always best to verify pricing with your pharmacist.
| Scenario | Brand-Name Daliresp (500mcg, 30 tablets) | Generic Roflumilast (500mcg, 30 tablets) |
|---|---|---|
| Uninsured Cash Price (Retail) | ~$450 - $565 | ~$40 - $100+ |
| With Pharmacy Discount Card | ~$20 - $30 | ~$20 - $30 |
| With Manufacturer Coupon (Commercial) | $25 per month (if eligible) | Not applicable (coupons are for brand) |
| With Standard Insurance Copay | Varies widely, potentially high | Significantly lower than brand copay |
| With Medicare Part D | Copay ranges vary; can be high | Lower cost, depends on plan and phase |
Programs for Reducing Costs
If the cost of Daliresp or roflumilast is a barrier, there are multiple options available to help you save money.
Prescription Discount Cards and Coupons
Many websites and apps offer free coupons and discount cards that can significantly lower the cost of both brand-name and generic medications. By presenting a card from providers like SingleCare or GoodRx, you can often access a much lower price, sometimes as low as $20-$30 for a 30-day supply, regardless of your insurance status.
Manufacturer Savings Programs
The maker of Daliresp, AstraZeneca, offers a savings program specifically for eligible, commercially insured, and cash-paying patients. This program can bring the cost for a 30-day supply down to as little as $25. However, this offer is not valid for patients on state or federally funded programs like Medicare or Medicaid.
Patient Assistance Programs (PAPs)
For uninsured or underinsured patients who meet certain income criteria, Patient Assistance Programs can provide medication at no cost or a very low cost. These are often run by non-profit organizations or pharmaceutical companies.
- Patient Advocate Foundation: This organization has a Co-Pay Relief program that can help eligible patients with their copays, co-insurance, and deductibles.
- Simplefill: This is a service that helps patients apply for and enroll in patient assistance programs they may be eligible for.
Other Cost-Saving Strategies
- Price Comparison: Not all pharmacies charge the same amount. Prices can differ based on the pharmacy chain and location, so comparing prices is always a smart move.
- International Pharmacies: In some cases, reputable international online pharmacies may offer lower prices, but caution is advised. Always ensure the pharmacy is accredited and the product is legitimate.
Conclusion
While the sticker price for brand-name Daliresp can be a deterrent, patients have several pathways to significantly lower their out-of-pocket costs. The most impactful is the availability of the generic roflumilast, which is a much more affordable option. Beyond the generic, utilizing discount cards from services like SingleCare or enrolling in manufacturer or third-party patient assistance programs can make this essential COPD medication financially accessible. By exploring all available avenues, patients can ensure they receive the necessary treatment without an overwhelming financial burden.
